Foresite Capital Management III’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-2,393,612
| Closed | -$45.1M | – | 13 |
|
|
2019
Q3 | $45.1M | Sell |
2,393,612
-548,518
| -19% | -$6.27M | 17.24% | 2 |
|
|
2019
Q2 | $34.6M | Hold |
2,942,130
| – | – | 11.36% | 3 |
|
|
2019
Q1 | $40.2M | Hold |
2,942,130
| – | – | 10.45% | 3 |
|
|
2018
Q4 | $30.2M | Hold |
2,942,130
| – | – | 9.9% | 3 |
|
|
2018
Q3 | $49M | Hold |
2,942,130
| – | – | 10.81% | 3 |
|
|
2018
Q2 | $46.5M | Hold |
2,942,130
| – | – | 10.01% | 3 |
|
|
2018
Q1 | $37.4M | Buy |
2,942,130
+95,000
| +3% | +$1.37M | 8.14% | 4 |
|
|
2017
Q4 | $32.6M | Sell |
2,847,130
-95,073
| -3% | -$1.06M | 9.15% | 3 |
|
|
2017
Q3 | $36M | Buy |
2,942,203
+765,000
| +35% | +$7.98M | 9.93% | 2 |
|
|
2017
Q2 | $24.9M | Buy |
2,177,203
+547,981
| +34% | +$10.1M | 8.14% | 3 |
|
|
2017
Q1 | $33.9M | Buy |
1,629,222
+894
| +0.1% | +$19.8K | 13.01% | 2 |
|
|
2016
Q4 | $33.9M | Buy |
1,628,328
+42,645
| +3% | +$1.11M | 14.72% | 3 |
|
|
2016
Q3 | $52M | Sell |
1,585,683
-14,500
| -0.9% | -$442K | 24.29% | 2 |
|
|
2016
Q2 | $40M | Buy |
1,600,183
+321,613
| +25% | +$8.7M | 27.42% | 1 |
|
|
2016
Q1 | $31.3M | Buy |
1,278,570
+1,048,675
| +456% | +$24.3M | 24.23% | 1 |
|
|
2015
Q4 | $7.59M | Buy |
+229,895
| New | +$7.77M | 6.73% | 3 |
|
Foresite Capital Management III's ALDR Position: Q4 2019 in Review
Foresite Capital Management III sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 2,393,612 shares — an estimated $45.1M sold.
Foresite Capital Management III first reported a position in ALDR in Q4 2015 and held it in 16 quarters. The position peaked at $52M in Q3 2016. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Foresite Capital Management III reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Foresite Capital Management III sold 2,393,612 Alder Biopharmaceuticals shares in Q4 2019, an estimated $45.1M.
- Foresite Capital Management III first reported a position in Alder Biopharmaceuticals in Q4 2015 and held it in 16 quarters.
- Foresite Capital Management III's Alder Biopharmaceuticals position peaked at $52M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Foresite Capital Management III's 13F filing for Q4 2019, filed 14 Feb 2020.